Principia Biopharma Finds $12.5M

San Francisco-based Principia Biopharma, a pharmaceuticals firm developing small molecule drugs aimed at treating inflammatory, autoimmune diseases, and cancer, has raised $12.5M in a second tranche of funding. The funding came from New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital. The company said the funding will go towards advancing its lead compounds towards the clinic and to develop additional programs. More information »